Video

VIDEO: Public testimony gets heated at FDA panel meeting on morcellation


 

AT AN FDA ADVISORY COMMITTEE MEETING

SILVER SPRING, MD. – Power morcellation devices should be never used for gynecologic procedures, Dr. Hooman Noorchashm testified to a Food and Drug Administration expert panel on July ll.

He called out members of the FDA Obstetrics and Gynecology Devices Panel Advisory Committee by name, seeking to shame them into action to disallow power morcellation for suspected uterine fibroids.

"Is this a safe and logical device?" said Dr. Noorchashm, a cardiothoracic surgeon at Brigham and Women’s Hospital in Boston. "The only classification for this device is banned – unsafe, illogical, incorrect, and deadly."

Dr. Noorchashm’s wife, Dr. Amy Reed, had a hysterectomy with morcellation for suspected fibroids. Biopsy later confirmed sarcoma was present. Use of power morcellation caused tumor cells to spread, upstaging her sarcoma to stage IV.

dfulton@frontlinemedcom.com

On Twitter @denisefulton

Recommended Reading

Transvaginal ultrasonography of ovarian cyst
MDedge ObGyn
Hemorrhagic ovarian cysts: One entity with many appearances
MDedge ObGyn
Obesity and gynecologic surgery, part 2
MDedge ObGyn
Gynecologic cancer patients treated at high-volume hospitals live longer
MDedge ObGyn
ASCO: Extend adjuvant endocrine therapy to 10 years
MDedge ObGyn
Immunotherapy shows promise in metastatic cervical cancer
MDedge ObGyn
Cancer survivors have higher medical costs
MDedge ObGyn
VIDEO: Team approach is best for successful oncofertility clinic
MDedge ObGyn
Uterine adenomyosis: Noninvasive diagnosis
MDedge ObGyn
FDA panel addresses risks of power morcellators in fibroid surgery
MDedge ObGyn

Related Articles